Takuma Yokoyama
Overview
Explore the profile of Takuma Yokoyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakayama K, Sahara J, Fujimoto M, Yagisawa Y, Kobata K, Kawagoe H, et al.
J Pharm Biomed Anal
. 2024 Jul;
249:116372.
PMID: 39079353
We explored the feasibility of high-speed and high-accuracy quantification of active pharmaceutical ingredient (API) content in tablet products by near-infrared (NIR) spectroscopy to improve the reliability of pharmaceuticals. For this...
2.
Kawagoe H, Sera H, Sahara J, Akai S, Watanabe K, Shinoyama K, et al.
Sci Rep
. 2023 Oct;
13(1):17261.
PMID: 37828139
Although time-stretch spectroscopy is an emerging ultrafast spectroscopic technique, the applications in industrial fields have been limited due to the low output power caused by undesirable nonlinear effects occurred in...
3.
Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, et al.
Cancer Sci
. 2023 May;
114(8):3330-3341.
PMID: 37183528
The global phase III KEYNOTE-407 (NCT02775435) trial showed that pembrolizumab plus chemotherapy prolonged overall and progression-free survival (OS/PFS) versus placebo plus chemotherapy in patients with metastatic squamous non-small-cell lung cancer...
4.
Naka G, Yokoyama T, Usui K, Ishida H, Kishi K, Uemura K, et al.
Jpn J Clin Oncol
. 2022 Mar;
52(7):791-794.
PMID: 35323965
Osimertinib is active against T790M-positive epidermal growth factor receptor mutant non-small cell lung cancer. We enrolled 122 sensitive epidermal growth factor receptor mutant non-small cell lung cancer patients who were...
5.
Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, et al.
ERJ Open Res
. 2020 Jun;
6(2).
PMID: 32494570
Background: Chemotherapy-induced acute exacerbation (AEx) of idiopathic interstitial pneumonias (IIPs) seriously compromises the success of treatment of Japanese lung cancer patients. Here, we conducted a nationwide surveillance to clarify the...
6.
Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, et al.
Cancer
. 2020 Jun;
126(16):3648-3656.
PMID: 32484914
Background: A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S-1 after induction therapy with carboplatin plus S-1 in patients with advanced...
7.
Saraya T, Fujiwara M, Yokoyama T, Takata S, Oka T, Ishii H, et al.
Intern Med
. 2019 Oct;
59(3):415-419.
PMID: 31588078
A 60-year-old woman with a 20-year history of myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis visited our hospital due to productive cough and a low-grade fever for several weeks. Thoracic computed...
8.
Usui K, Yokoyama T, Naka G, Ishida H, Kishi K, Uemura K, et al.
Jpn J Clin Oncol
. 2019 Feb;
49(6):554-558.
PMID: 30809659
Background: Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation....
9.
Inui T, Watanabe M, Nakamoto K, Sada M, Hirata A, Nakamura M, et al.
Exp Lung Res
. 2019 Jan;
44(7):323-331.
PMID: 30676127
Rationale: Neutrophilic airway inflammation plays a central role in chronic obstructive pulmonary disease (COPD). CXC chemokine ligand (CXCL)1 is a neutrophil chemokine involved in the pathogenesis of COPD. However, its...
10.
Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, et al.
Thorac Cancer
. 2018 Dec;
10(2):395-400.
PMID: 30536780
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore,...